After graduating from Brown Medical School, Dr. Lahijani completed the Combined Internal Medicine/Psychiatry Residency Program at Rush University Medical Center in Chicago. She then served as a physician in the areas of primary care and triple diagnosis (addiction, HIV, mental health). Thereafter, Dr. Lahijani completed the Psychosomatic Medicine Fellowship at the Feinberg School of Medicine of Northwestern University where she worked at the Lurie Comprehensive Cancer Center. During her fellowship, she also served as a psychiatric oncologist at Memorial Sloan Kettering Cancer Center.
Dr. Lahijani joined the faculty of Stanford University School of Medicine in 2015 as a Clinical Assistant Professor of Psychiatry and Behavioral Sciences. Since her initial appointment, Dr. Lahijani has served as the lead psychiatric oncologist at the Stanford Cancer Center where she provides psychiatric consultation services to patients with cancer and collaborates closely with her hematology and oncology colleagues to deliver comprehensive cancer care.
In 2019, she was appointed as the Medical Director of the Stanford Cancer Center Psychosocial Oncology Program where she works in Stanford Cancer Center leadership and oversees the development and operationalization of psychiatric consultation for patients with cancer. Dr. Lahijani also attends on the medical/surgical units, ICUs and in the emergency department at Stanford Hospital and Clinics to provide care for patients with complex medical and psychiatric diagnoses and to teach psychiatry, internal medicine, and neurology trainees. Dr. Lahijani is trained in and administers several psychotherapeutic modalities, including Meaning Centered Psychotherapy and Dignity Therapy, in addition to practicing psychopharmacology.
As Faculty of the Advancing Communication Excellence at Stanford, Dr. Lahijani leads foundational workshops for faculty and staff to advance communication skills with patients, families, and their colleagues. She is committed to developing and contributing to efforts that focus on relationship centered skills and provider wellness.
Her clinical and scholarly interests include the interface of medicine and psychiatry, pharmacology, psycho-oncology, collaborative care models, psychotherapy for the medically ill, interdisciplinary medical education, teaching, and writing.
- Internal Medicine
- Psychosomatic Medicine
- Psychiatric Oncology
Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
Member, Stanford Cancer Institute
Medical Director, Stanford Cancer Center Psychosocial Oncology Program (2019 - Present)
Honors & Awards
Research Methods in Supportive Oncology, Harvard Medical School (2018)
Best Case Report Poster, Academy of Consultation Liaison Psychiatry (2018)
Innovator Grant Award, Stanford Department of Psychiatry and Behavioral Sciences (2019)
Stanford Leadership Development Program, Stanford University School of Medicine (2020-2021)
Faculty Professional and Leadership Development Award, Stanford Department of Psychiatry and Behavioral Sciences (2021)
Chairman's Award, Stanford Department of Psychiatry and Behavioral Sciences (2021)
Boards, Advisory Committees, Professional Organizations
Member, American College of Physicians (2007 - Present)
Member, Association of Medicine and Psychiatry (2009 - Present)
Member, Academy of Consultation Liaison Psychiatry (2014 - Present)
Member, American Psychosocial Oncology Society (2015 - Present)
Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2014)
Board Certification: American Board of Psychiatry and Neurology, Psychosomatic Medicine (2015)
Fellowship: Northwestern University Feinberg School of Medicine (2015) IL
Residency: Rush University Medical Center (2012)
Medical Education: Brown Medical School (2007) RI
Fit for Duty: Lessons learned from outpatient and homebound HCT to prepare family caregivers for home-based care.
Transplantation and cellular therapy
In the past decade, the demand for home-based care has been amplified by the COVID-19 pandemic. Home-based care has significant benefits for patients, their families, and healthcare systems, but relies on the often invisible workforce of family and friend caregivers who shoulder essential health care responsibilities often with inadequate training and support. Hematopoietic cell transplantation (HCT), a potentially curative but intensive treatment for many patients with blood disorders, is increasingly offered in home-based care settings and necessitates the involvement of family caregivers for significant patient care responsibilities. However, guidelines for supporting and preparing HCT caregivers to effectively care for their loved ones at home have not yet been established. Informed by extant literature and our collective experiences as clinicians and researchers who care for diverse patients with hematologic malignancies undergoing HCT, we provide considerations and recommendations to better support and prepare family caregivers in home-based HCT and, by extension, family caregivers supporting patients with other serious illnesses at home. We suggest tangible ways to screen family caregivers for distress and care delivery challenges, educate and train them to prepare for their caregiving role, and create an infrastructure of support for family caregivers within this emerging care delivery model.
View details for DOI 10.1016/j.jtct.2022.12.014
View details for PubMedID 36572386
View details for PubMedCentralID PMC9780643
Long-Term Cognitive and Neuropsychiatric Outcomes in Adults Who Have Received Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - a Pilot Feasibility Study
AMER SOC HEMATOLOGY. 2022: 5201-5202
View details for DOI 10.1182/blood-2022-168229
View details for Web of Science ID 000893223205100
Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study
SPRINGER. 2022: S145
View details for Web of Science ID 000922594700300
Biobehavioral Implications of Chimeric Antigen Receptor T-cell Therapy: Current State and Future Directions.
Transplantation and cellular therapy
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical responses in hematologic malignancies. Recent advances in CAR T-cell therapy have expanded its application into other populations including older patients and those with central nervous system and solid tumors. Although its clinical efficacy has been excellent for some malignancies, CAR T-cell therapy is associated with severe and even life-threatening immune-mediated toxicities, including cytokine release syndrome (CRS) and neurotoxicity. There is a strong body of scientific evidence highlighting the connection between immune activation and neurocognitive and psychological phenomena. To date, there has been limited investigation into this relationship in the context of immunotherapy. In this review, we present a biobehavioral framework to inform current and future cellular therapy research and contribute to improving the multidimensional outcomes of patients receiving CAR T-cell therapy.
View details for DOI 10.1016/j.jtct.2022.09.029
View details for PubMedID 36208728
Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.
LIPPINCOTT WILLIAMS & WILKINS. 2022: 278
View details for Web of Science ID 000891944700277
Do PROs Tell the Whole Story? Differential Outcomes Based on PatientReported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy
AMER SOC HEMATOLOGY. 2021
View details for DOI 10.1182/blood-2021-145746
View details for Web of Science ID 000736413904116
Psych-Onc on the cutting edge: CAR-T cell therapy and the role of the psychiatric oncologist
WILEY. 2021: 46
View details for Web of Science ID 000624698300100
SLEEP DISTURBANCES IN CANCER AND COVID: TREATMENT DILEMMAS AND INTERVENTION BASED PROGRAMS
WILEY. 2021: 15
View details for Web of Science ID 000624698300022
Perceptions of time spent pursuing cancer care among patients, caregivers, and oncology professionals.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Patients with cancer spend significant time receiving treatment and recovering from side effects. Little is known about how patients and their caregivers perceive time spent receiving cancer treatment and how this impacts health-related quality of life (HRQoL). Our study aims to characterize perceptions of time invested in receiving cancer therapy as experienced by patients, caregivers, and oncology professionals.We conducted semi-structured interviews with patients undergoing treatment for advanced lung cancer and melanoma, their informal caregivers, and oncology professionals (physicians, nurses, social workers, and chaplains). Participants received and provided care at a tertiary cancer center. Interviews were audiorecorded and transcribed verbatim. Transcripts were analyzed qualitatively using predominantly inductive coding to identify themes relating to time perception and cancer care.We interviewed 29 participants (11 patients, 7 informal caregivers, and 11 oncology professionals) and found they consistently differentiated between time remaining in life ("existential time") and time required to manage cancer treatment and symptoms ("chronological time"). Patients and caregivers reported distress around the mechanics of oncologic care that interrupted their daily lives (hobbies, activities). Participants described the impact of time invested in cancer care on dimensions of quality of life, ranging from minimal to substantial negative impact.We found that the time spent undergoing cancer treatment affects well-being and often prevents patients and caregivers from participating in meaningful activities. The investment of personal time undergoing cancer therapy for patients with advanced solid tumors merits further study and can enhance communication between patients, caregivers, and their oncologists.
View details for DOI 10.1007/s00520-020-05763-9
View details for PubMedID 32935204
- What is Involved in Hematopoietic Cell Transplantation Facing Transplantation: A Guide for Patients and Their Families edited by Sher, Y., Stern, T. MGH Psychiatry Academy. 2020: 163–172
- Clinical Dilemmas in Evaluating and Treating Sleep Disorders in Cancer Journal of Psychosocial Oncology Research and Practice 2019; 1 (1S): e9
- Mental Health Prior to Hematopoietic Cell Transplantation Psychosocial Care of End Organ Disease and Transplant Patients edited by Sher, Y., Maldonado, J. 2018: 401–411
- Cultural Aspects of Transplantation Psychosocial Care of End Organ Disease and Transplant Patients edited by Sher, Y., Maldonado, J. 2018: 539–546
Medical Complications of Psychiatric Treatment An Update
CRITICAL CARE CLINICS
2017; 33 (3): 713-+
Psychiatric medications are used commonly in hospitalized patients and are particularly indicated in patients who are critically ill to manage many conditions. Due to their many indications in the intensive care unit (ICU), psychiatric medications should be closely monitored in these medically compromised patients for adverse reactions and medical complications because they may affect essentially all organ systems. These range from life-threatening reactions to other less significant effects, such as sedation, to other detrimental complications, such as pancreatitis. Knowledge of psychopharmacology as well as the diagnosis and treatment of these complications is imperative in treating patients in the ICU.
View details for PubMedID 28601142
Managing Depression in Patients With Cancer
2016; 30 (7): 665–71
View details for Web of Science ID 000381789400010
View details for PubMedID 27422114
- Hypertension Associated with Psychiatric Conditions Clinical Overview Elsevier. 2021
- How Can I Handle the Loss of Family, Friends, and Co-Workers? Facing COVID: A Guide for Patients and Their Families MGH Psychiatry Academy. 2021: 161-164
Neurosyphilis Presenting as Mania and Psychosis After Incidental Treatment With Cephalexin: A Case Report and Literature Review of Jarisch-Herxheimer Reactions
2020; 61 (2): 177–80
View details for Web of Science ID 000519299000009
View details for PubMedID 31331661
Symposia & Podiums
WILEY. 2020: 5
View details for DOI 10.1002/pon.5327
View details for Web of Science ID 000514591500002
Somatic Complaints and Anxiety "I Wish the Doctor Would Figure Out What's Wrong With Me"
PRACTICAL STRATEGIES IN GERIATRIC MENTAL HEALTH: CASES AND APPROACHES
View details for Web of Science ID 000555001100006
- Somatic Complaints and Anxiety in Older Adults Practical Strategies in Geriatric Mental Health Cases and Approaches edited by Dunn, L., Cassidy-Eagle, E. American Psychiatric Association Publishing. 2019; 1
Supervision of Auxiliary Health Care Providers Roles, Goals, and Learning Opportunities
SUPERVISION IN PSYCHIATRIC PRACTICE: PRACTICAL APPROACHES ACROSS VENUES AND PROVIDERS
View details for Web of Science ID 000550978200046
- Supervision of Auxiliary Health Care Providers: Roles, Goals, and Learning Opportunities Supervision in Psychiatric Practice: Practical Approaches Across Venues and Providers edited by DeGolia, S., Corcoran, K. 2019: 375–382
- Neurosyphilis Presenting as Mania and Psychosis after Incidental Treatment with Cephalexin: A Case Report. Academy of Consultation Liaison Psychiatry 2018
- Buspirone for the Treatment of Severe Antipsychotic-Induced Extrapyramidal Symptoms Academy of Psychosomatic Medicine 2015
- Palliative and End-of-Life-Care of Borderline Personality Disorder in Older Adults Borderline personality disorder in older adults: Emphasis on care in institutional settings edited by Hategan, A., Bourgeois, J., Xiong, G. 2015: 123–128
- Insights from Collaborative Care: A Review of the Evidence for Depression and Diabetes Psychiatric Annals 2015; 45 (8)
- Levofloxacin-Induced Fulminant Hepatic Failure American College of Physicians 2008
- Acute Hepatits B Presenting as Pericarditis American College of Physicians 2006